PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 12970580-6 2003 Co-treatment of PC3/AR cells with SKF-525A, a nonselective inhibitor of cytochrome P450 (CYP) enzymes, enhanced the antiandrogenic effect, indicating that the antiandrogenic effect is caused by intact species of DEPE constituents. Proadifen 34-42 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 72-87 24753822-0 2014 A Comparison of the In Vitro Inhibitory Effects of Thelephoric Acid and SKF-525A on Human Cytochrome P450 Activity. Proadifen 72-80 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 90-105 16980726-6 2006 In contrast, we observed that CYP450 inhibitors such as SKF-525A, 17-octadecynoic acid, 1-aminobenzotriazole, and 6-(2-propargyloxyphenyl)hexanoic acid reduced 12(S)-HETE levels, 3T6 fibroblast growth, and DNA synthesis induced by FBS. Proadifen 56-64 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 30-36 16162970-8 2005 Potent cytotoxic activity of ET-743 after 120 h treatment was observed, which could be increased in combination with the CYP inhibitors metyrapone (3A4), phenanthrene (substrate for 2E1, 3A4), piperonyl butoxide (3A), proadifen (2C9, 2E1, 3A4), ritonavir (3A4), and warfarin (2C9, 2C19). Proadifen 218-227 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 121-124 12970580-6 2003 Co-treatment of PC3/AR cells with SKF-525A, a nonselective inhibitor of cytochrome P450 (CYP) enzymes, enhanced the antiandrogenic effect, indicating that the antiandrogenic effect is caused by intact species of DEPE constituents. Proadifen 34-42 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 89-92 15618748-11 2003 ABT, SKF-525A, and ketoconazole showed different selectivity and had a wide range of Ki values for the drug oxidations catalyzed by human CYP enzymes. Proadifen 5-13 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 138-141 12388057-6 2003 We found that in high endothelial venular cells (SVEC4-10), multiple inhibitors of CYP450 monooxygenases (SKF-525a, ketoconazole, troleandomycin, itraconazole) attenuated TNF-alpha induction of MAdCAM-1, whereas NADPH oxidase inhibition (PR-39) did not. Proadifen 106-114 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 83-89 15618748-12 2003 Therefore, we conclude that inhibitory studies designed to predict the contribution of CYP enzymes to the metabolism of certain compounds should be performed using multiple CYP inhibitors, such as ABT, SKF-525A, and ketoconazole. Proadifen 202-210 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 87-90 1539615-4 1992 Two separate studies have shown that Med I"s vasodepressor action is inhibited by four procedures: mixing with Tween 20; treatment with n-butyl boronic acid; treatment of the assay animal with SKF 525A, an inhibitor of cytochrome P-450; and removing the liver from the circulation. Proadifen 193-201 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 219-235 11357344-4 2001 EHF EMR was also inefficient with cells pretreated with proadifen, an inhibitor of epoxygenase (cytochrome P-450). Proadifen 56-65 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 96-112 8386241-4 1993 Covalent binding required oxygen and NADPH, and was decreased by the nucleophile glutathione and by the cytochrome P-450 inhibitors SKF 525-A, piperonyl butoxide and troleandomycin (an inhibitor of the cytochrome P-450 3A subfamily). Proadifen 132-141 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 104-120 11059564-1 2000 We studied the effects of inhibition of cytochrome P-450 by proadifen (SKF525A) on the processes induced in myeloid leukemia HL-60 cells by all-trans-retinoic acid (ATRA). Proadifen 71-78 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 40-56 7736913-5 1995 The oxidation of both losartan and the putative aldehyde intermediate E3179 was catalyzed by the microsomal fraction, required both NADPH and molecular oxygen, and was inhibited by SKF 525-A, implicating cytochrome P450 (CYP). Proadifen 181-190 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 204-219 7745225-3 1995 CCl4-induced changes in hepatic biochemical parameters by reducing cytochrome P-450, by comparing the effects of colchicine and SKF 525-A, a well-known inhibitor of cytochrome P-450. Proadifen 128-137 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 165-181 8207335-6 1994 The formation of these metabolites is unaffected by cyclooxygenase and lipoxygenase inhibitors (indomethacin, diclofenac and BW755C) but inhibited by cytochrome P450 enzyme inhibitors such as carbon monoxide, SKF-525A and clotrimazole. Proadifen 209-217 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 150-165 1458471-7 1992 Conversely, clotrimazole and SKF525A, inhibitors of cytochrome P-450 enzymes, had effects similar to those of ketoconazole on HT29-S-B6 cells whereas metronidazole and secnidazole, other azole derivatives which do not inhibit cytochrome P-450 enzymes, had no effect. Proadifen 29-36 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 52-68 1458471-7 1992 Conversely, clotrimazole and SKF525A, inhibitors of cytochrome P-450 enzymes, had effects similar to those of ketoconazole on HT29-S-B6 cells whereas metronidazole and secnidazole, other azole derivatives which do not inhibit cytochrome P-450 enzymes, had no effect. Proadifen 29-36 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 226-242 2168548-0 1990 Is the sigma opiate receptor a proadifen-sensitive subform of cytochrome P-450? Proadifen 31-40 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 62-78 2703963-8 1989 Several cytochrome P-450 inhibitors [metyrapone, 8-methoxypsoralen, 2-(4,6-dichloro-biphenyloxy) ethylamine, alpha-naphthoflavone and cimetidine] decreased the biliary excretion of AA-GS, although SKF 525-A and piperonyl butoxide did not. Proadifen 197-206 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 8-24 2559440-6 1989 Inhibitors of cytochrome P-450 such as SKF-525A, metyrapone and n-octylamine dose-dependently inhibited the DS production. Proadifen 39-47 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 14-30 2474030-9 1989 LTB4-omega-hydroxylase activity was inhibited (greater than 90%) by carbon monoxide or 2-diethylaminoethyl-2,2-diphenylvalerate hydrochloride (SKF-525A) (1 mM), whereas alpha-naphthoflavone produced only moderate (13%) or no effects. Proadifen 87-141 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 0-22 2474030-9 1989 LTB4-omega-hydroxylase activity was inhibited (greater than 90%) by carbon monoxide or 2-diethylaminoethyl-2,2-diphenylvalerate hydrochloride (SKF-525A) (1 mM), whereas alpha-naphthoflavone produced only moderate (13%) or no effects. Proadifen 143-151 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 0-22 6457649-1 1981 Metyrapone and SKF-525A, together with amphenone B, a structural analogue of metyrapone, which are all inhibitors of cytochrome P-450-mediated reactions, were shown to inhibit the arachidonic acid-induced aggregation of human platelets. Proadifen 15-23 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 117-133 3109426-1 1987 SKF 525-A (proadifen), a well-known inhibitor of drug metabolism and cytochrome P-450 activity, stimulated the release of prostacyclin (PGI2) from the rabbit aorta in vitro. Proadifen 0-9 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 69-85 4044832-7 1985 The LTB4 omega-hydroxylase was inhibited significantly by carbon monoxide, ferricytochrome c, SKF-525A, and Triton X-100, but was not affected by alpha-naphthoflavone, azide, cyanide, catalase, and superoxide dismutase. Proadifen 94-102 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 4-26 3594722-0 1987 Defining the active site of cytochrome P-450: the crystal and molecular structure of an inhibitor, SKF-525A. Proadifen 99-107 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 28-44 3594722-1 1987 The crystal and molecular structure of the cytochrome P-450 inhibitor, SKF-525A [2-(diethylamino)ethyl 2,2-diphenylpentenoate; proadifen hydrochloride] is described. Proadifen 71-79 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 43-59 3594722-1 1987 The crystal and molecular structure of the cytochrome P-450 inhibitor, SKF-525A [2-(diethylamino)ethyl 2,2-diphenylpentenoate; proadifen hydrochloride] is described. Proadifen 127-150 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 43-59 3109426-1 1987 SKF 525-A (proadifen), a well-known inhibitor of drug metabolism and cytochrome P-450 activity, stimulated the release of prostacyclin (PGI2) from the rabbit aorta in vitro. Proadifen 11-20 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 69-85 428008-6 1979 Metyrapone and SKF 525-A inhibit covalent binding of the hormone to cytoplasmic macromolecules, which suggests participation of the cytochrome P-450 system in covalent binding of the hormone. Proadifen 15-24 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 132-148 954149-0 1976 A new class of inhibitory cytochrome P-450 complexes formed during metabolism: a comparison with amphetamine and SKF 525-A type complexes. Proadifen 113-122 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 26-42 4153511-0 1974 The formation of complexes absorbing at 455 nm from cytochrome P-450 and metabloites of compounds related to SKF 525-A. Proadifen 109-118 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 52-68